Phase 3, Randomized Controlled Trial of Atrasentan in Patients with Nonmetastatic Hormone-Refractory Prostate Cancer

BACKGROUND: Atrasentan is a potent, oral, selective endothelin-A (ET(A)) receptor antagonist with clinical activity in patients with hormone-refractory prostate cancer (HRPC). This reports the results of a Phase 3, randomized, double-blind, placebo-controlled trial of atrasentan in patients with non...

Full description

Saved in:
Bibliographic Details
Main Authors: Nelson, Joel B., Love, William, Chin, Joseph L., Saad, Fred, Schulman, Claude C., Sleep, Darryl J., Qian, Jiang, Steinberg, Joyce, Carducci, Michael
Format: Artigo
Language:Inglês
Published: 2008
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3085548/
https://ncbi.nlm.nih.gov/pubmed/18785254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23864
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items